DaVita Labs appoints vp and general manager
Chronic kidney disease laboratory hires Leslie Mirani
Mirani brings to DaVita Labs more than 25 years’ experience in commercial sales and marketing – primarily renal-focused – in the pharmaceutical industry. She previously worked for Human Genome Sciences as an immunology sales director and as vice president for Amgen’s nephrology business unit for 18 years.
DaVita Labs has 86,700ft2 dedicated to its clinical diagnostic laboratories between its two locations in Fort Lauderdale and DeLand, Florida, US.
You may also like
Manufacturing
Adragos Pharma appoints Kostas Rengis as Chief Executive Officer
Munich, Germany – May 7th, 2026 – Adragos Pharma, a global contract development and manufacturing organisation (CDMO), today announced the appointment of Konstantinos (Kostas) Rengis as its new Chief Executive officer, succeeding Dr. Andreas Raabe, who founded the company and has led it over the past six years
Research & Development
Syngene strengthens leadership team with two key appointments to support next phase of growth
Abhijit Zutshi joins as CCO and Maninder Kapoor Puri as CHRO. India/U.S./UK, 1 May 2026: Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the Abhijit Zutshi as Chief Commercial Officer (CCO) and Maninder Kapoor Puri as Chief Human Resources Officer (CHRO), effective 1 May 2026
Training & Education
Length vs weight in medicated implant quality control
In medicated implant manufacturing, quality control must do more than confirm dimensional conformity. It must help protect the integrity of the delivered unit. This raises a practical technical question: when assessing implant quality, which physical attribute is the more defensible primary control for dose integrity, implant length or implant weight?
Manufacturing
Lonza delivers strong performance in Q1 2026 in line with expectations and confirms full-year Outlook 2026
Basel, Switzerland, 8 May 2026 – In its qualitative Q1 2026 business update, Lonza1 reported a strong performance across its CDMO business in line with the expected trajectory for Full-Year 2026. As expected, due to a lower prior year base, campaign timing and product releases, and planned site shutdowns, CER sales growth and CORE EBITDA margin will be notably stronger in the first half of 2026 than in the second half
Cell & Gene Therapy
Merck signs five-year deal to provide testing services for Genetix Biotherapeutics' gene therapies
Merck has entered a five-year agreement to deliver end-to-end analytical and biosafety release testing for Genetix Biotherapeutics' three FDA-approved gene therapies targeting sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy
Research & Development
Fujifilm develops cyclic peptide screening platform for challenging membrane protein targets
The compa has created a novel mRNA display screening methodology capable of identifying high-affinity cyclic peptides against multi-pass transmembrane proteins on living cell surfaces, overcoming a key limitation of conventional approaches that require protein isolation and risk disrupting native structures
Ingredients
The impact of Brexit on raw materials testing for the pharmaceutical industry (2026 update)
Since the UK departed from the EU, the pharmaceutical regulatory landscape has undergone significant and lasting change; whereas early uncertainty has largely subsided, the system has evolved into a stable but more complex dual framework